rho激酶抑制剂联合弥可保治疗糖尿病周围神经病变的临床观察.doc

Rho激酶抑制剂联合弥可保治疗糖尿病周围神经病变 摘要 目的：观察Rho激酶抑制剂联合弥可保治疗糖尿病周围神经病变的疗效。方法：对66例2型糖尿病周围神经病变患者随机分为治疗组与对照组，在常规给予糖尿病饮食和应用口服降糖药物或胰岛素的治疗基础上，治疗组应用Rho激酶抑制剂盐酸法舒地尔注射液联合弥可保注射液静脉滴注，对照组应用弥可保注射液静脉滴注。结果：治疗组与对照组总有效率分别为97.2%和70.0%。治疗组疗效明显优于对照组(pO.01)。治疗后，治疗组神经传导速度明显改善，与对照组相比差异有统计学意义(P0.05)。结论：Rho激酶抑制剂盐酸法舒地尔联用弥可保治疗糖尿病周围神经病变的疗效肯定。可有效改善临床症状，提高患者生活质量。 关键词 Rho激酶抑制剂 弥可保 糖尿病周围神经病变 中图分类号 R 589.1 R745.7 文献标识码 A Effect of combined treatment of Rho kinase inhibitors and Meth- ycobalamin on diabetic peripheral neuropathy Chang Qiong, Dai Qingxiang Affiliated Hospital Of Qinghai University，Xining(810001) Abstract objective：To observe the clinical effect of combined treatment of Rho kinase inhibitors and Methycobalamin on diabetic peripheral neuropathy(DPN) . Method：66 patients with type 2 diabetes mellitus peripheral neuropathy were randomly divided into the observer groups and control group， In conventional applications for diabetes diet and oral hypoglycemic drugs or insulin treatment based ，on the observation group application of Rho-kinase inhibitor fasudil injection and Methycobal intravenous injection, the control group Methycobal intravenous injection drip only. Results：Observation group and control group, the total effective rates were 97.2% and 70%. Clinical observation group significantly better than the control group (p O.01)。The observation group after treatment nerve conduction velocity improved significantly compared with control group statistically significant difference (P0．05).Conclusion：Rho kinase inhibitor fasudil combined with methylcobalamin treatment of diabetic peripheral neuropathy sure.Can effectively improve the clinical symptoms, improve patients quality of life. ?Key words Rho kinase inhibitors, Methycobalamin, Diabetic peripheral neuropathy 糖尿病致残致死的主要原因是糖尿病的慢性合并症，糖尿病周围神经病变（diabetic peripheral neuropathy,DPN)是糖尿病最常见的慢性并发症，以肢体疼痛麻木为突出临床表现,其中以远端对称性、感觉运动性、多发性周围神经病变最常见。2型糖尿病患者随着年龄和病程进展更易出现DPN，经神经电生理检测，其患病率高达90％以上[1]，严重者可致残，严重影响患者生活质量，积极治疗糖尿病周围神经病变对减少糖尿病致残、致死率有重要